GP-1614

TRAI		F INFORMATION DISCLO nder 37 CFR 1.97(b) or 1.97			Docket No. 31140B
In Re Ar	pplication Of: C	Gustavo C. Rodriguez and Regina	Salas Whitaker		
	Serial No.	Filing Date	Examiner		Group Art Unit
_1	10/051662	January 18, 2002			1614
OFF	The Information of a national apthree months of application: before	Assistant Con Washing	ddress to: nmissioner for Patents gton, D.C. 20231 CFR 1.97(b) I herewith is being filed within I prosecution application und I stage as set forth in 37 CFI ction on the merits, or before	n three n er 37 C R 1.491 the maili	FEB 2. 2 2002 nonths of the fing FR 1.53(d); within in an international
		37 (CFR 1.97(c)		
2.	CFR 1.97(b), pr Final Action un otherwise closes	Disclosure Statement submitted rovided that the Information Disclosure 37 CFR 1.113, a Notice of prosecution in the application, and the specified in 37 CFR 1.97(e)	closure Statement is filed be of Allowance under 37 CFR and is accompanied by one o	tore the 1.311,	or an Adom that
		OR			6 20 6 160
	☐ the fee se	et forth in 37 CFR 1.17(p).			CEIVED B 2 6 2002 NTER 1600/2900
1					

F INFORMATION DISCLO Inder 37 CFR 1.97(b) or 1.97	OSURE STATEMENT (c))	Docket No. 31140B
Gustavo C. Rodriguez and Regina	Salas Whitaker	
Filing Date January 18, 2002	Examiner	Group Art Unit 1614
		IIN D COMPOUND
mmissioner is hereby authorized by. A duplicate copy of this sheet he amount of my overpayment. Any additional fee required. Transmission by Facsimile* Transmission to charge deposite imile transmitted to the United States Office (F	Certificate of Maili I certify that this documer 02/07/02 as first class mail und addressed to the Assistar Washington, D.C. 20231. Signature of Pers Raymond N. Nimrod, Reg. N	ing by First Class Mail Int and fee is being deposited with the U.S. Postal Service der 37 C.F.R. 1.8 and is nt Commissioner for Patents, Son Mailing Correspondence No. 31,987
ay only be used if paying by A Signature Signature	Dated: February 7, 2002	
	Filing Date January 18, 2002 FOVARIAN CANCER BY ADM Only complete if Applicant elements of the amount of the amo	Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete if Applicant elects to pay the fee set forth in 37 (on the complete in applicant elects to pay the fee set forth in 37 (on the complete in applicant elects to pay the fee set forth in 37 (on the complete in applicant elects to pay the fee set forth in 37 (on the complete in applicant elects to pay the fee set forth in 37 (on the complete in applicant elects to pay the fee set fort

Serial No.: 10/051662

FIB 15 2007

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gustavo C. Rodriguez

Serial No.: 10/051662

Filed: January 18, 2002

For: PREVENTION OF OVARIAN CANCER

File No.: 31140B

INFORMATION DISCLOSURE STATEMENT

To: Assistant Commissioner For Patents

BY ADMINISTRATION OF A VITAMIN D COMPOUND

Washington, DC 20231

Sir:

The following is a disclosure of art. To Applicants' knowledge, a first Office Action on the merits has not yet been mailed.

The references submitted for consideration by the Office are set forth on the enclosed PTO Forms 1449 (21 pages). Legible copies of the references are included herewith.

This Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited in this statement is, or is considered to be, material to patentability as defined in 1.56(b) or that no other information material to patentability as defined in 37 C.F.R. §1.56(b) exists.

Serial No.: 09/798,453 File No.: 31168

Should there be any fees required in connection with this submission, please charge Deposit Account No. 18-1942.

Dated: February 7, 2002

Respectfully submitted,

Raymond N. Nimrod Registration No. 31,987 200 South Michigan Avenue

Suite 1000

Chicago, Illinois 60604 Telephone: (312) 408-0855

CERTIFICATE OF MAILING

I, Raymond N. Nimrod, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with postage prepaid, in an envelope addressed to: Assistant Commissioner For Patents, Washington, DC 20231, on February 7, 2002.

Dated: February 7, 2002

Raymond N. Nimrod

	•			*.	ATTY DOCKET NO. 31140		ERIALINO.	05 66 2	R
/	PINEC	TION DISCLOSUR			Gustavo C. Rodrig			. A. H.	III
10	•	several sheets if nece	ssary)		FILING		POLID	<u>" > B</u>	$\frac{\Omega}{\Omega}$
	FEB 1 5	2002			01/18/0)2	·	16EEO 05	
	Arre	and the same of th	U	.S. PATEN	T DOCUMENTS			200k	₩
*EXAMINE	RNIET	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FES DATE	_
Ø	Ai	4,757,061	07/12/88	Faustir	ni, F. et al.	514	177	02/10/86	
	A2	4,760,053	07/26/88	Labrie	, F.	514	15	07/31/86	
	А3	4,808,578	02/28/89	Faustin	ni, F. et al.	514	177	12/15/86	-
	A4	4,808,616	02/28/89	Buzzet	ti, F. et al.	514	177	07/07/86	
	A5	4,814,327	03/21/89	Ottow,	E. et al.	514	179	07/24/87	
	A6	4,840,943	06/20/89	Buzzet	ti, F. et al.	514	177	06/14/87	
	A7	4,870,069	09/26/89	Ottow,	E. et al.	514	179	01/25/88	
	A8	4,904,650	02/27/90	Buzzet	ti, F. et al.	514	177	07/26/88	
	A9	4,954,790	09/04/90	Barbei	·, R.G.	332	164	11/15/89	
	A10	5,006,518	04/09/91	Mogui	lewsky, M.	514	179	12/30/88	
6	A11	5,081,114	01/14/92	Gourv	est, J-F et al.	514	177	12/24/90	
	L	1	FOF	REIGN PAT	ENT DOCUMENTS				
1		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLA	NO
1)	Ві	WO 98/10771	03/19/98	WIPO					
	B2	WO 95/26730	10/12/95	PCT					
	В3	0 253 607 A1	07/13/87	Europ	e				
	B4	0 253 607 B1	07/13/87	Europ	e		_		
h	B5	0 628 312 A1	02/14/94	Europ	e		<u> </u>		
	1	OTHER DOCUM	MENTS (Includ	ling Autho	or, Title, Date, Pertin	ent Pages, Etc.,)		
6				-		····			
							_		_
EXAMIN	NER /	m	3,		DATE CONSIDERED	3/19/	03		
*EXAMI	NER: Init	ial if reference considered, whe	ther or not citation	is in confor	mance with MPEP 609;	Draw line through c	itation if not in o	conformance a	and not
conside	red. Incli	ude copy of this form with next of	communication to	applicant.					
		,		-	2000.00	Patent and Tradem	ark Office * U.S. DE	PARTMENT OF	OMMERCE

Form PTO-A820 (also form PTO-1449)

CRMATICAN DISCLOSURE CITATION
(Use several sheets if necessary)

FEB 1 5 2002

ATTY DOCKET NO. 31140B SERIAL NO.

10/051662

Gustavo C. Rodriguez and Regina Salas Whitaker

FILING

01/18/02

GROUP

1614

A13 5,089,488 02/18/92 Ottow, E. et al. 514 179 10/11/90 A14 5,227,375 07/13/93 Labrie, F. et al. 514 172 02/08/90 A15 5,362,720 11/08/94 Labrie, F. 514 169 02/08/93 A16 5,364,847 11/15/94 Labrie, F. et al. 514 182 10/22/92 A17 5,434,146 07/18/95 Labrie, F. et al. 514 169 06/24/92 A18 5,461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS TRANSLATION TRANSLAT		\ F	EB 1 5 2002		01/18/0	2		1614	
A12 5,086,047 02/04/92 Gourvest, J-F et al. 514 177 12/24/90		V	A STATE OF THE STA	U	I.S. PATENT DOCUMENTS				
A12 S.086,047 02/04/92 Gourvest, J-F et al. 514 177 12/24/90 A13 5.089,488 02/18/92 Ottow, E. et al. 514 179 10/11/90 A14 5.227.375 07/13/93 Labrie, F. et al. 514 172 02/08/90 A15 5.362,720 11/08/94 Labrie, F. 514 169 02/08/93 A16 5.364,847 11/15/94 Labrie, F. et al. 514 182 10/22/92 A17 5.434,146 07/18/95 Labrie, F. et al. 514 169 06/24/92 A18 5.461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5.486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5.496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5.502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4.594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS TRANSLATION YES No. No.			DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		
A13 5,089,488 02/18/92 Ottow, E. et al. 514 179 10/11/90 A14 5,227,375 07/13/93 Labrie, F. et al. 514 172 02/08/90 A15 5,362,720 11/08/94 Labrie, F. 514 169 02/08/93 A16 5,364,847 11/15/94 Labrie, F. et al. 514 182 10/22/92 A17 5,434,146 07/18/95 Labrie, F. et al. 514 169 06/24/92 A18 5,461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS TRANSLATION TRANSLAT		A12	5,086,047	02/04/92	Gourvest, J-F et al.	514	177	12/24/90	
A15 5,362,720 11/08/94 Labrie, F. 514 169 02/08/93 A16 5,364,847 11/15/94 Labrie, F. et al. 514 182 10/22/92 A17 5,434,146 07/18/95 Labrie, F. et al. 514 169 06/24/92 A18 5,461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES IN	1	A13	5,089,488	02/18/92	Ottow, E. et al.	514	179	10/11/90	
A16 5,364,847	1	A14	5,227,375	07/13/93	Labrie, F. et al.	514	172	02/08/90	
A17 5,434,146 07/18/95 Labrie, F. et al. 514 169 06/24/92 A18 5,461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO	1	A15	5,362,720	11/08/94	Labrie, F.	514	169	02/08/93	
A18 5,461,041 10/24/95 Bergink, E.W. et al. 514 178 01/29/94 A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO		A16	5,364,847	11/15/94	Labrie, F. et al.	514	182	10/22/92	
A19 5,486,511 01/23/96 Weintraub, P.M. et al. 514 178 05/02/94 A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO		A17	5,434,146	07/18/95	Labrie, F. et al.	514	169	06/24/92	
A20 5,496,813 03/05/96 Eugster, C. et al. 514 172 08/13/92 A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS	1	A18	5,461,041	10/24/95	Bergink, E.W. et al.	514	178	01/29/94	
A21 5,502,044 03/26/96 Buzzetti, F. et al. 514 177 02/14/94 A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS	1	A19	5,486,511	01/23/96	Weintraub, P.M. et al.	514	178	05/02/94	
A22 4,594,340 06/10/86 Partridge, J.J. et al. 514 167 11/29/84 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NOTHER DOCUMENTS.	_	A20	5,496,813	03/05/96	Eugster, C. et al.	514	172	08/13/92	
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NUMBER NUMBER		A21	5,502,044	03/26/96	Buzzetti, F. et al.	514	177	02/14/94	
DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO OTHER DOCUMENTS. (Including Author Title, Date, Pertinent Pages, Etc.)	7	A22	4,594,340	06/10/86	Partridge, J.J. et al.	514	167	11/29/84	
OTHER DOCUMENTS. (Including Author Title Date, Pertinent Pages, Etc.)	7			FOI	REIGN PATENT DOCUMENTS			<u>-</u>	
OTHER DOCUMENTS. (Including Author Title Date Perlinent Pages, Etc.)			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS		ATION
OTHER DOCUMENTS. (Including Author Title Date Perlinent Pages, Etc.)									
OTHER DOCUMENTS. (Including Author Title Date Pertinent Pages, Etc.)									
OTHER DOCUMENTS. (Including Author Title Date Pertinent Pages, Etc.)									
OTHER DOCUMENTS. (Including Author Title Date Perlinent Pages, Etc.)									
OTHER DOCUMENTS. (Including Author Title Date Pertinent Pages, Etc.)		-							
		<u> </u>	OTHER DOCUM	MENTS (Includ	ding Author. Title. Date. Pertin	ent Pages, Etc.	.)		
							33 H	\mathcal{P}	
							- N		
HCEN FE CO							7 6 21 7 1601		
RECEIN HCENTER 1800	YAMINE	- FE X			DATE CONSIDERED	3/,	130 N	म	
DATE CONSIDERED 3/18/10/27	"WHITE		YIM	<u></u>		4//	99/11 7		

considered. Include copy of this form with next communication to applicant.

(Use several effects if necessary)

ATTY DOCKET NO.	SERIAL NO.
31140B	10/051662
}	

Gustavo C. Rodriguez and Regina Salas Whitaker

GROUP

1614

	- (FEB 1 5 2002 (E)		01/18/0)2		1614	
	1	The Thought	U	J.S. PATENT DOCUMENTS				
KAMINER ITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
R	A23	4,800,198	01/24/89	DuLuca, H.F. et al.	514	167	04/30/87	
1	A24	5,190,935	03/02/93	Binderup, E.T. et al.	514	167	07/04/90	
1	A25	5,206,229	04/27/93	Calverly, M.J. et al.	514	167	04/07/89	
1	A26	5,246,925	09/21/93	DuLuca, H.F. et al.	514	167	10/13/92	
1	A27	5,278,155	01/11/94	Ikekawa, N. et al.	514	167	06/05/91	-
	A28	5,373,004	12/13/94	DeLuca, H.F. et al.	514	167	11/24/93	
1	A29	5,374,629	12/20/94	Calverley, M.J. et al.	514	167	03/22/91	
	A30	5,380,720	01/10/95	DeLuca, H.F. et al.	514	167	05/11/93	
	A31	5,387,582	02/07/95	Hansen, K.	514	167	12/10/90	
	A32	5,389,622	02/14/95	Posner, G.H. et al.	514	167	06/04/93	
B	A33	5,401,731	03/28/95	Calverley, M.J. et al.	514	167	08/30/93	
9	.l.——		FOI	REIGN PATENT DOCUMENTS				
	T	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	ATION NO
	1							
		OTHER DOCU	MENTS (Includ	ding Author, Title, Date, Pertin	ent Pages, Etc.)		
		OTHER DOCU	MENTS (Includ	ding Author, Title, Date, Pertin				
						ECH.	7	
						TECH CENTER 1800/2002	ECI	
EXAMINE	FR		1	DATE CONSIDERED	3/19/	6 200	<u> </u>	

considered. Include copy of this form with next communication to applicant.

INFORMATION TO CLOSURE CITATION (Use several subjects if necessary)

FEB 1 5 2002

ATTY DOCKET NO. 31140B

SERIAL NO.

10/051662

Gustavo C. Rodriguez and Regina Salas Whitaker

FILING

01/18/02

GROUP 1614

KAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
1TIAL	A34	5,411,949	05/02/95	Neef, G. et al.	514	167	01/20/92
Y	A35	5,428,029	06/27/95	Doran, T.I. et al.	514	167	11/24/93
-}-	A36	5,446,035	08/29/95	Neef, G. et al.	514	167	09/16/94
	A37	5,451,574	09/19/95	Baggiolini, E.G. et al.	514	167	01/18/94
	A38	5,484,782	01/16/96	DeLuca, H.F. et al.	514	167	05/16/95
1	A39	5,512,554	04/30/96	Baggiolini, E.G. et al.	514	167	04/11/95
1	A40	5,532,228	07/02/96	Neef, G. et al.	514	167	06/01/93
1	A41	5,536,713	07/16/96	DuLuca, H.F. et al.	514	167	03/20/95
T	A42	5,547,947	08/20/96	Dore, B.T., et al.	514	167	11/30/94
	A43	5,554,599	09/10/96	GrueSorenen, G. et al.	514	167	12/17/93
3	A44	3,608,075	09/21/71	Glen et al.	424	238	07/28/69
<i>,)</i>			FOI	REIGN PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
			18.7				
		OTHER DOCUM	MENTS (Includ	ding Author, Title, Date, Pertine	ent Pages, Etc.)	
AMINE	R /	12	\sim	DATE CONSIDERED	3/14	/ 123	

MATION SCLOSURE CITATION (Use several stigets if necessary)

FEB 1 5 2002

ATTY	DOCKET	١	10.
	3	31	140I

SERIAL NO.

10/051662

Gustavo C. Rodriguez and Regina Salas Whitaker

FILING

01/18/02

GROUP

1614

AMINER		WENT & TRAUDING		NAME	CLASS	SUBCLASS	FILING DATE	:
TIAL		DOCUMENT NUMBER	DATE	NAME			IF APPROPR	
D	A45	3,957,982	05/18/76	Lachnit-Fixson et al.	424	238	12/23/74	
	A46	3,969,502	07/09/74	Lachnit-Fixson	424	239	07/09/74	
 	A47	4,390,531	07/28/83	Edgren	424	239	08/10/81	
1	A48	4,530,839	07/23/85	Pasquale	514	171	09/26/83	
1	A49	4,544,554	10/01/85	Pasquale	514	170	05/04/84	
	A50	4,616,006	10/07/86	Pasquale	514	170	06/13/85	
	A51	4,621,079	11/04/86	Lachnit-Fixson et al.	514	170	12/21/84	
-	A52	4,628,051	12/09/86	Pasquale	514	170	06/11/85	
\top	A53	4,817,819	04/04/89	Kelly	221	2	02/17/87	
+	A54	4,921,843	05/01/90	Pasquale	514	170	10/20/88	
2	A55	4,931,283	06/05/90	Tsuk	424	449	03/26/87	<u> </u>
<u> </u>	1		FOI	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	LATION
				<u> </u>				
			<u></u>	THE DATE OF THE PARTY.	The Page 5 Sta		<u> </u>	
	1	OTHER DOCU	MENTS (Includ	ding Author, Title, Date, Pertine	ent Pages, Lic.	,		_
					_			
AMINE	ER _	A		DATE CONSIDERED	3/19	107		

considered. Include copy of this form with next communication to applicant.

RMATION DISCLOSURE CITATION (Use several speets if necessary)
FEB 1 5 2002 英

ATTY DOCKET NO. 31140B SERIAL NO.

10/051662

Gustavo C. Rodriguez and Regina Salas Whitaker

FILING

GROUP

		TOWN TO THE MODELLES		I.S. PATENT DOCUMENTS		т	Υ	
(AMINER IT <u>I</u> AL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
3	A56	4,933,184	06/12/90	Tsuk	424	449	04/03/87	
1	A57	4,962,098	10/09/90	Boissonneault	514	170	04/20/89	
	A58	5,108,995	04/28/92	Casper	514	170	04/26/90	
	A59	5,210,081	05/11/93	Reveendranath et al.	514	179	02/26/92	
	A60	5,256,421	10/26/93	Casper	424	449	11/10/92	
	A61	5,262,408	11/16/93	Bergink	514	182	12/12/91	
	A62	5,280,023	01/18/94	Ehrlich et al.	514	177	02/10/92	
	A63	5,288,717	02/22/94	Raveendranath et al.	514	179	12/03/92	
	A64	5,314,694	05/24/94	Gale et al.	424	448	03/26/93	
	A65	5,382,573	01/17/95	Casper	514	170	10/29/93	
22	A66	5,418,228	05/23/95	Bennick	514	182	01/14/94	
<u></u>	<u> </u>		FOF	REIGN PATENT DOCUMENTS			·	
	T	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	LATION
							123	1.0
								1-
	Ė							
	-							
								-
		OTHER DOCU	MENTS (Includ	ding Author, Title, Date, Pertin	nent Pages, Etc.)		
	1	V	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
	ļ.							
	+							
	0.10							
XAMINE	R			DATE CONSIDERED	3/19			
		1 10 00			11/0	1 1 7		

Form PTO-A820 (also form PTO-1449)

considered. Include copy of this form with next communication to applicant.

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

INFORMATION DESCLOSURE CITATION
(Use several state in necessary)

ATTY DOCKET NO.	SERIAL NO.
31140B	10/051662
Custous C. Padriguez and	Dogina Salas Whitakar
Gustavo C. Rodriguez and	
Gustavo C. Rodriguez and FILING 01/18/02	Regina Salas Whitaker GROUP 1614

A67 5,422,119 06/06/95 Casper 424 449 01/0 A68 5,468,736 11/21/95 Hodgen 514 179 02/2 A69 5,595,970 01/21/97 Garfield, et al. 514 12 11/2 A70 5,620,705 04/15/97 Dong et al. 424 451 08/0 A71 5,633,011 05/27/97 Dong et al. 424 451 08/0 A72 5,741,786 04/21/98 Hamersma et al. 514 173 10/2 A73 5,747,480 05/05/98 Gast 514 179 04/0 A74 5,770,227 06/23/98 Dong et al. 424 480 07/0 A75 4,780,497 07/14/98 Miller et al. 514 414 04/0 A76 5,783,208 07/21/98 Yenkateshwaran et al. 514 177 05/0 A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/0	CLASS SUBCLASS FILING DATE IF APPROPRIATE 424 449 01/03/94 514 179 02/25/93 514 12 11/16/93 424 472 05/16/95 424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 41 41 07/19/96 514 177 05/08/95
	424 449 01/03/94 514 179 02/25/93 514 12 11/16/93 424 472 05/16/95 424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96
A68 5,468,736	514 179 02/25/93 514 12 11/16/93 424 472 05/16/95 424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 4al. 424 448 07/19/96 514 177 05/08/95
A69 5,595,970 01/21/97 Garfield, et al. 514 12 11// A70 5,620,705 04/15/97 Dong et al. 424 472 05/ A71 5,633,011 05/27/97 Dong et al. 424 451 08// A72 5,741,786 04/21/98 Hamersma et al. 514 173 10// A73 5,747,480 05/05/98 Gast 514 179 04// A74 5,770,227 06/23/98 Dong et al. 424 480 07/ A75 4,780,497 07/14/98 Miller et al. 514 414 04// A76 5,783,208 07/21/98 Yenkateshwaran et al. 514 177 05// A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05//	514 12 11/16/93 424 472 05/16/95 424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A70 5,620,705 04/15/97 Dong et al. 424 472 05/ A71 5,633,011 05/27/97 Dong et al. 424 451 08/0 A72 5,741,786 04/21/98 Hamersma et al. 514 173 10/3 A73 5,747,480 05/05/98 Gast 514 179 04/3 A74 5,770,227 06/23/98 Dong et al. 424 480 07/3 A75 4,780,497 07/14/98 Miller et al. 514 414 04/3 A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/3 A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4	424 472 05/16/95 424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A71 5,633,011 05/27/97 Dong et al. 424 451 08/4 A72 5,741,786 04/21/98 Hamersma et al. 514 173 10/3 A73 5,747,480 05/05/98 Gast 514 179 04/3 A74 5,770,227 06/23/98 Dong et al. 424 480 07/ A75 4,780,497 07/14/98 Miller et al. 514 414 04/ A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/ A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4 FOREIGN PATENT DOCUMENTS	424 451 08/04/94 514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A72 5,741,786 04/21/98 Hamersma et al. 514 173 10/3 A73 5,747,480 05/05/98 Gast 514 179 04/3 A74 5,770,227 06/23/98 Dong et al. 424 480 07/3 A75 4,780,497 07/14/98 Miller et al. 514 414 04/3 A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/3 A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4 FOREIGN PATENT DOCUMENTS CLASS SUBCLASS SUBCLASS	514 173 10/24/95 514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A73 5,747,480 05/05/98 Gast 514 179 04/3 A74 5,770,227 06/23/98 Dong et al. 424 480 07/3 A75 4,780,497 07/14/98 Miller et al. 514 414 04/3 A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/3 A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/3 FOREIGN PATENT DOCUMENTS	514 179 04/17/97 424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A74 5,770,227 06/23/98 Dong et al. 424 480 07/ A75 4,780,497 07/14/98 Miller et al. 514 414 04/ A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/ A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4	424 480 07/17/96 514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A75 4,780,497 07/14/98 Miller et al. 514 414 04/ A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/ A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4 FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS	514 414 04/14/97 t al. 424 448 07/19/96 514 177 05/08/95
A76 5,783,208 07/21/98 Yenkateshwaran et al. 424 448 07/ A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/4 FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS	t al. 424 448 07/19/96 514 177 05/08/95
A77 5,811,416 09/22/98 Chwalisz et al. 514 177 05/0 FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS	514 177 05/08/95
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS	
COUNTRY CLASS SUBCLASS	NTS
I I DOCHMENT NUMBER I DATE I COUNTRY I CLASS I SUBCLASS	
	CLASS SUBCLASS TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	

Form PTO-A820 (also form PTO-1449)

Copyright 1994-97 LegalStar

considered. Include copy of this form with next communication to applicant.

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 1 5 2002

ATTY DOCKET NO.	SERIAL NO.
31140B	10/051662
Tustava C. Padriguez and	Dagina Salas Whitakar
Gustavo C. Rodriguez and	Regina Salas Whitaker GROUP

	\	150 1 2 5005 B		01/	/18/02		1614	
		TO THE PROPERTY.		J.S. PATENT DOCUMENTS			_	
EXAMINER NITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
71	A78	5,827,876	10/27/98	Sabatucci	514	448	04/08/97	
1	A79	5,855,906	01/05/99	McClay	424	433	12/19/95	
	A80	5,858,405	01/21/99	Gast	424	464	07/02/97	
	A81	5,876,746	03/02/99	Jona et al.	424	449	06/06/96	
	A82	5,880,137	03/09/99	Miller et al.	514	323	04/29/98	
	A83	5,888,543	03/30/99	Gast	424	464	07/02/97	
	A84	5,891,868	04/06/99	Cummings et al.	514	178	11/21/97	
	A85	5,898,038	04/27/99	Yallampalli et al.	514	742	03/19/96	
	A86	5,922,349	07/13/99	Elliesen et al.	424	449	09/27/96	
	A87	5,922,542	07/13/99	Ralston et al.	435	6	02/28/97	
4)	A88	5,948,775	09/07/99	Koko et al.	514	212	03/12/98	
	l		FOF	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	COUNTRY CLASS SUBCLASS		TRANSL YES	ATION NO
								-
						<u> </u>		
		OTHER DOCUM	IENTS (Includ	ling Author, Title, Date, Pe	ertinent Pages Etc.)		
						ECH	표	
				DATE CONSIDER 3 / / is in conformance with MPEP 6		CENTER	EB 2 6	

Form PTO-A820 (also form PTO-1449) Copyright 1994 LegalStar

considered. Include copy of this form with next communication to applicant.

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

SERIAL NO. ATTY DOCKET NO. 10/051662 31140B INFORMATION DISCLOSURE CITATION Gustavo C. Rodriguez and Regina Salas Whitaker (Use several speets if necessary) GROUP FILING FEB, 1 5' 2002 01/18/02 1614 **U.S. PATENT DOCUMENTS** FILING DATE *EXAMINER SUBCLASS CLASS NAME DOCUMENT NUMBER DATE IF APPROPRIATE INITIAL 514 177 05/29/98 A89 10/05/99 Cook et al. 5,962,444 449 10/02/98 424 A90 5,972,377 10/26/99 Jona et al. 04/14/97 514 415 A91 11/16/99 Miller et al. 5,985,910 01/12/98 Washburn et al. 514 182 A92 11/30/99 5,994,337 01/17/97 435 A93 5,998,137 12/07/99 Grainter et al. 285 02/17/98 514 A94 12/14/99 Edwards et al. 6,001,846 514 176 05/25/99 Cook et al. A95 01/18/00 6,015,805 Cook et al. 514 176 03/06/98 A96 02/01/00 6,020,328 177 09/13/96 514 A97 02/22/00 Rodriguez 6,028,064 167 06/11/97 514 A98 03/07/00 Rodriguez et al. 6,034,074 179 12/16/99 514 A99 10/30/01 Rodriguez 6,310,054 B1 **FOREIGN PATENT DOCUMENTS** TRANSLATION SUBCLASS COUNTRY **CLASS** DOCUMENT NUMBER DATE YES NO (Including Author, Title, Date, Pertinent Pages, Etc.) OTHER DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER'

DATE CONSIDERED

INFORMATION DISCLOSURE CITATION (Use several simples if necessary)

ATTY DOCKET NO. 31140B	SERIAL NO. 10/051662				
Gustavo C. Rodriguez and Regina Salas Whitaker					

	_\	158 1 2 mar 2			01/18	l l		1614	
		ATENT & TRADER	Ų	.S. PATENT	DOCUMENTS				
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE	
11	A100	6,319,911 B1	11/20/01	Rodrigu	1ez	514	170	07/16/98	
		1							
	-								
			9						
· _ ·									
				_					
			FOR	REIGN PATE	NT DOCUMENTS			1	
	<u> </u>	DOCUMENT NUMBER	DATE	T	COUNTRY	CLASS	SUBCLASS		LATION
								YES	NO
	 							-	
			***					1	
	ļ		<u> </u>						
	<u> </u>	OTHER POCUL	AENTS /Inclus	ting Author	r, Title, Date, Perti	inent Pages Etc.)	<u></u>	<u> </u>
		OTHER DOCUM	MENTS (MICIAL	mig Admo	, Thie, Date, 1 orth	nont rages, Etc.,			
							j	런	
-								ב כ	Z)
							יבטוו טבועובו	FEB 2	Ω
EXAMINE	R	2			DATE CONSIDERE	5D 3/19/	13	6 200	<u> </u>
*EXAMINE	ER: Init	ial if reference considered, whe	ther or not citation communication to	is in conforr	nance with MPEP 609	; Draw line through c	itation if no	conforman	nd not

Form PTO-A820 (also form PTO-1449)

Docket Number (Optional)
31140B
Application Number
31140B
10/051662
Applicant(s)
Gustavo C. Rodriguez and Regina Salas Whitaker
Filing Date
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER	QTIER DOCUMENTS (Inchaing Name), They Date, I criment 1 4800, 2009				
INITIAL	Adenovirus-Medicated Procedure For High-Efficiency DNA Transfer," Biochemistry, 36(1):224-232 (1997).				
		Arends, M.J. et al., "Apoptosis: Mechanisms And Roles In Pathology," Int. Rev. Exp. Pathol., 32:223-254 (1991).			
	C2				
	C3	Arrick, B.A., et al., "Differential Regulation Of Three Transforming Growth Factor b Species In Human Breast Cancer Cell Lines By Estradiol," Cancer Res., 50:299-303 (1990).			
	C4	Bai, W. et al., "Differential Phosphorylation Of Chicken Progesterone Receptor In Hormone-Dependent And Ligand-Independent Activation," J. Biol. Chem., 272(16):10457-10463 (1997).			
	C5	Bates, R.C. et al. "Involvement Of Integrins In Cell Survival," Cancer Metastasis Rev, 14(3):191-203 (1995).			
	C6	Berchuck, A. et al., "Regulation Of Growth Of Normal Ovarian Epithelial Cells And Ovarian Cancer Cell Lines By Transforming Growth, Factor-Beta," Am. J. Obstet. Gynecol., 166:676-84 (1992).			
	C7	Berchuck, A., et al., "The Role Of Peptide Growth Factors In Epithelial Ovarian Cancer," Obstet. Gynecol, 75:255-62 (1990)			
	C8	Brenner, R.M. et al., "Cyclic Changes In The Primate Oviduct And Endometrium. In: <i>The Physiology Of Reproduction</i> ," Knobil, E. et al., (eds.), New York: Raven Press, pp. 541-569 (1994).			
	С9	Bu, S.Z. et al., "Progesterone Induces Apoptosis And Up-Regulation of p53 Expression In Human Ovarian Carcinoma Cell Lines," Cancer, 79:1944-1950 (1997).			
	C10	Bundesverband der Pharmazeutishen Industrie, "Rote liste 1995," Ecv. Editio Cantor, <i>Aulendorf</i> (DE), pp. 75023-75024 (1995).			
	CII	Chan, L.N. et al., "N-(4-Hydroxyphenyl) Retinamide Prevents Development Of Tlymphomas In AKR/J Mice," Anticancer Research, 17:499-503 (1997).			
B	C12	Cohen, J.J., "Apoptosis," Immun. Today, 14:126-130 (1993).			
EXAMINER		DATE CONSIDERED			

EXAMINER

0/19/07

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		OF I	31140B	10/051662		
INE		ATION DESCLOSURE CITATION	Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker			
		(Use several sheet) if necessary)	Filing Date	Group Art Unit		
	1_	FEB 1 5 2002 \$	01/18/02	1614		
*EXAMINER		OTHER DOCUMENTS (Including Author,	Title, Date, Pertinent Pages, Etc.)			
INITIAL		Dolia D et al "N-(4-hydroxynhenyl) Keilnami	de Induces Apoptosis Of Malignant	Hemopoletic Cell Lines Including Those		
12	C13	Unresponsive To Retinoic Acid," Cancer Res., 5.	3(<i>24)</i> :0030-41 (1773).			
الميك	(13					
,		Eguchi, Y. et al., "Isolation And Characterizatic Lymphoid And Neuronal Organs In Adult And	on Of The Chicken bcl-2 Gene: Expr	ession In A Variety Of Tissues Including <i>0(16)</i> :4187-4192 (1992).		
	C14	Lymphold And Neuronal Organs in Adult And	Emoryo, Tracted From England			
		el-Bayoumy, K. et al., "Chemo Prevention Of C (1995).	ancer By Organoselenium Compoun	ds," J. Cell. Biochem, Suppl., 22:92-100		
	C15	(1773).		- 0-2		
		Ellis, R. et al., "Mechanisms of Cell Death," An	n. Rev. Cell. Bio., 17:003-098 (1991).			
	C16					
	-	Evans, D.L. et al., "Molecular Evolution And S	ocendary Structural Conservation In	The B-Cell Lymphoma Leukemia 2		
		(bcl-2) family Of Proto-Oncogene Products," J.	Mol. Evol., 41(6):775-83 (1995).	<u>-</u>		
	C17					
		Fredrickson, T.N. et al., "Ovarian Tumors Of T	The Hen," Environ Health Perspect, 7	3:35-44 (1987).		
		Treatienson, This et any Commercial				
	C18					
	-	Gentry, L.E. et al., "Type I Transforming Grov Precursor Polypeptides In Chinese Hamster Ov	vth Factor-Beta: Amplified Expressions: Colle " Mal. Call. Biol. 7:3418-2	on And Secretion Of Mature And		
	C19	Precursor Polypeptides in Chinese Hamster Ov	ary Cens, 1970. Cens Blon, 715 176 2	, (2501)		
	Cis	T. V. C. C. C. C. C. C.				
		Grimes et al., "Primary Prevention Of Gynecol	ogic Cancers," Am. J. Obstetrics And	Gynecology, 172(1):227-235 (1995).		
	C20					
			I I N I And Malianant Ovaria	on Enithelial Cells By Transforming		
		Havrilesky, L.J., et al., "Regulation Of Apoptos Growth Factor-Beta," Cancer Research, 55:944	sis in Normal And Manghant Ovalla -948 (February 15, 1995).	in Epithenai Cens by Transforming		
	C21					
	 	Hickey, M.J., et al., "Metabolic And Endocrino	logic Effects Of Steroidal Contracep	tion Obstetrics," Ch. 24, J. Sciarra,		
		Editor, 1996 revised edition, Lippincott, Philad	elphia, pp. 1-14 (1996).			
	C22					
		Hotchkiss, J. et al., "The Menstrual Cycle And	Its Neuroendocrine Control," In: Th	ne Physiology Of Reproduction, Knobil, E.		
		et al. (eds.), New York: Raven Press, pp. 711-73	36 (1994).			
	C23					
		Hurteau, J.A., et al., "Transforming Growth F	actor-Beta Inhibits Proliferation Of	Human Ovarian Cancer cells Obtained		
	C24	From Ascites," Cancer, 74:93-99 (1994).				
01						
EXAMINER	}		DATE CONSIDERED	19223		
		M	l			
*EXAMINER	: Initial i	f citation considered, whether or not citation is in confo	ormance with MPEP Section 609; Draw li	ne through citation if not in conformance and		
not considered	l. Includ	le copy of this form with next communication to applica	nt.			

P09B/REV04

•	_	OF I	31140B	10/051662	
IN	FORM	MITON DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Gustavo C. Rodriguez and Regi		
	(!	FEB 1 5 2002 E	Filing Date Group Art Unit 01/18/02 1614		
*EXAMINER	V	CENT L TRIS	or, Title, Date, Pertinent Pages, Etc.)		
N	C25	Johnson, A.J. et al., "Expression of bcl-2 And 1 57:1096-1103 (1997).			
	C26	Kaiserman-Abramof, L et al., "Ultrastructural Am J. Anat., pp. 13-30 (1989).	l Epithelial Conation Of The Primate En	dometrium (Rhesus Monkey),"	
	C27	Lingeman, C.H., "Etiology Of Cancer Of The	Human Ovary," A Review, J. Natl. Canc	er Inst. m 53: 1603-1618 (1974).	
	C28	Lotan, R., "Retinoids In Cancer Chemo Preven	ntion, [Review] FASEB J., 10(9): 1031-10	139, (1996).	
	C29	Lumbiganon, P., "Depot-Medroxyprogesteron Contraception, 49: 203-209 (March 1994).	ie Acetate (DMPA) And Cancer Of The E	Indometrium And Ovary,"	
	C30	Mulheron, G.W., et al., "Rat ThecalInterstitial By Gonadotropin In Vitro," <i>Endocri</i> n, 129: 36	I Cells Express Transforming Growth Fa 58-374 (1991).	ctor-Beta Type 1 and 2 Is Regulated	
	C31	Mulheron, G.W. et al., "Rat Granulosa Cells E Acid Which Is Regulated By Fillide Stimulatin	Express Transforming Growth factor-Bet ag Hormone In Vetro," Endocrin, 126:17	a Type 2 Messenger Ribonucleic 77-1779 (1990).	
	C32	Mutch, D.G., et al., "Biology Of Epithelial Ove	erian Cancer," Clin. Obstet. Gynecol., 37:	406-422 (1994).	
	C33	O'Brien V. et al., "Expression Of THe Integrin Apoptosis Triggered By Serum Deprivation,"	n Alpha 5 Subunit In HT29 Colon Carcin Ex Cell. Res. 224(1): 208-213 (1996).	ioma Cells Suppresses	
	C34	Oberhammer, F.A., et al., "Induction Of Apop Growth Factor-Beta 1," Proc. Natl. Acad. Sci.	otosis In Cultured Hepatocytes And In Re USA, 89: 408-5412 (1992).	egressing Liver By Transforming	
	C35	Oridate N. et al., "Inhibition Of Proliferation Implications For Chemo Prevention," J. Cell.	And Injunction Of Apoptosis In Certical Biochem, Suppl. 23:80-86 (1995).	Carcinoma Cells By Retinoids:	
a	C36	Pasquele, R.M., et al. "Chemoprevention By S 1,2-dimethylhydrazine Adn Promoted By Oro	3-Adenosyl-L-Methionine Of Rat Liver C ttic Acid," Carcinogenesis 16(2): 427-30 (arcinogenesis Intiated by 1995).	
EXAMINER	1	2~~~	DATE CONSIDERED	103	
EXAMINER *EXAMINER:		if citation considered, whether or not citation is in confidence of this form with next communication to applic	oformance with MPEP Section 609; Draw line t		

			Docket Number (Optional)	Application Number			
	1	O.E.	31140B	10/051662			
IN	FORM O	ATION INSCLOSURE CITATION (Use several singless if necessary)	Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker				
	FE	B 1 5 2002 (\$)	Filing Date 01/18/02	Group Art Unit 1614			
*EXAMINER	A	MATER DOCUMENTS (Including Author, Title	le, Date, Pertinent Pages, Etc.)				
INITIAL		Plleiderer "di Problematik einer prophylaktischen	Chemotherapie, einer der Remissio	n bei der Therapie des			
0	C37	Ovarialkarzinoms, "Gerburstsh u. Frauenheilk, 360	(1970).				
	C38	Physician's Desk Reference 1996, Product Informa (1996).	tion, pp. 1871-1876, 2135-2138, 2601	-2604, 2759-2762, and 2813-2818			
	C39	Ponzoni, M. et al., "Differential Effects Of N-(4-hy. Apoptosis Versus Differentiation," Can. Res., 55(4)	droxyphenyl) Retinamide And Retin 1:853-61 (1995).	oic Acid On Neuroblastoma Cells:			
	C40	Qin, S., et al., "Cooperation Of Tyrosine Kinases p Oxidant Stress Signaling," Eur. J. Biochem, 236(2)	Qin, S., et al., "Cooperation Of Tyrosine Kinases p72syk and p53/561yn Regulates Calcium Mobilization In Chicken Oxidant Stress Signaling," Eur. J. Biochem, 236(2):443-9 (1996).				
	C41	Rampalli, A.M., et al., "Insulin Regulates Expressi Cell. Growth Differ., 6(8):945-53 (1995).	Rampalli, A.M., et al., "Insulin Regulates Expression Of <i>c-fos</i> And <i>c-jun</i> and Suppresses Apoptosis Of Lens Epithelial C <i>Cell. Growth Differ.</i> , 6(8):945-53 (1995).				
	C42	Reddy, B.S., et al., "Chemo Prevention Of Colon Carcinogenesis By Dietary Perillyl Alcohol," Cancer Res., 57(3):420-(1997).					
	C43	Roberts, A.B., et al. "Mechanistic Interrelationship Transforming Growth Factor-Beta," In: Cancer S Imperial Cancer Research Fund, pp. 205-217 (1992)	os Between Two Superfamilies: The Surveys, Vol. 14: Growth Regulation).	Steroid Retinoid Receptors And By Nuclear Hormone Receptors,			
	C44	Rodriguez, G.C., et al., "Epidermal Growth Factor Receptor Expression In Normal Ovarian Epithelium And Ovarian Cancer. II. Relationship Between Receptor Expression And Response To Epidermal Growth Factor," Am. J. Obstet. Gynes 164: 745-750 (1991).					
	C45	Rotello, R.J., et al., "Coordinated Regulation Of Apoptosis And Cell Proliferation By Transforming Growth Factor-Be Cultured Uterine Epithelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3412-3415 (1991).					
	C46	Rudel, H.W., "Pharmacology Of Contraceptive Steroids," Chapter 19, In: Gynecology and Obstetrics J. Sciarra, Editor, 1996 revised edition, Lippincott, Philadelphia, pp. 3-6 (1996).					
		Sankaranarayanan, R., et al., "Retinoids As Cance	er-Preventive Agents," [Review] IAR	C Sci. Publ., (139):47-59 (1996)			
	C47						
a	C48	Schildkraut, J.M. et al., "Relationship Between Lit Ovarian Cancer," J. National Cancer Institute, 89(fetime Ovulatory Cycles And Overex (13):932-938 (July 2, 1997).	pression Of Mutant p53 In Epithelial			
EXAMINER	2		DATE CONSIDERED 3/19/C	3			
		f citation considered, whether or not citation is in conforma	ance with MPEP Section 609; Draw line t	hrough citation if not in conformance and			

	6	EVA	31140B	10/051662
IN	FORM.	ATION EISCLOSURE CITATION (Use several press if necessary)	Applicant(s) Gustavo C. Rodriguez and R	egina Salas Whitaker
	-	8 1 5 2002 E	Filing Date 01/18/02	Group Art Unit
*EXAMINER	CAT	HER DOCUMENTS (Including Autho	r, Title, Date, Pertinent Pages, Etc.)	
INITIAL		Scott, J.S., "How To Induce Ovarian Cancer:	And How Not To," British Medical J.,	289:781-784 (September 29, 1984)
	C49			
	C50	Seewaldt, V.L. et al., "All-Trans-Retinoic Acid Epithelial Cells," Cell Growth Differ., 6(7):631	1 Mediates GI Arrest But Not Apoptos -41 (1995).	sis Of Normal Human Mammary
	C51	Syvala, H. et al., "Expression Of The Chicken Estrogen In Vivo," <i>Biochemical and Biophysic</i>	Progesterone Receptor Forms A And al Research Communications, 231:573	B Is Differentially Regulated By -576 (1997).
	C52	Taetle, R., et al., "Effects Of Transforming Gr Leukemia Cells," Cancer Research, 53:3386-33	rowth Factor-Beta 1 On Growth And 2 393 (1993).	Apoptosis Of Human Acute Myelogenous
	C53	Takayama, S. et al., "Evolutionary Conservat Oncoprotein," DNA Cell. Biol. 13(7):679-92 (1	ion Of Function Among Mammalian, 994).	Avian, And Viral Homologs Of The bcl-2
	C54	Thompson, H.J. et al., "Sulfone Metabolite Of (1997).	Sulindac; Inhibits Mammary Carcin	ogenesis," Cancer Res., 57(2):267-71
	C55	Thompson, H.J. et al., "Ip C. Comparison Of Carcinoma Cell Line," Carcinogenesis 15(2):1	The Effects Of An Organic And Inorg 83-6 (1994).	anic Form Of Selenium On A Mammary
	C56	Toma, S. et al., "Effects of Al-Trans-Retinoic Inhibition And Apoptosis Induction," Int. J. C	Acid And 13-Cis-Retinoic Acid On Br Cancer, 70(5):619-27 (1997).	east-Cancer Cell Lines: Growth
	C57	Vilgrasa, X. et al., "Differential Expression of 47(1):26-9 (1997).	bcl-2 and bcl-x During Chicken Speri	natogenesis," Mol. Reprod. Dev.,
	C58	Wakefield, L. et al., "Regulation Of Transford Superfamily," J. Cell. Sci. Suppl. 13:139-148 (ming Growth Factor-Beta Subtypes B 1990).	y Members Of The Steroid Hormone
	C59	Wijsman, J.H. et al., "A New Method To Dete J. Histochem. Cytochem., 41:7-12 (1993).	ect Apoptosis In Paraffin Sections: In	Situ End-Labeling Of Fragmented DNA,"
a	C60	Woolveridge, I., et at., "The Inhibition Of An- Domestic Hen (<i>Gallus domesticus</i>): Evidence F	drostenedione Production In Mature For The Involvement Of Progestins," (Thecal Cells From The Ovary Of The Steroids, 62:214-220 (1997).
EXAMINER		m	DATE CONSIDERED 3/19/	
*EXAMINER not considered	: Initial i	f citation considered, whether or not citation is in cont e copy of this form with next communication to applic	formance with MPEP Section 609; Draw licant.	ne through citation if not in conformance and

ATION SISCLOSURE CITATION (Use several sheets if necessary)

FEB 1 5 2002

Docket Number (Optional) 31140B

Application Number

10/051662

Applicant(s)
Gustavo C. Rodriguez and Regina Salas Whitaker

Filing Date

Group Art Unit

	LEB 15 AME			18/02	1614		
*EXAMINER	1	OTHER DOCUMENTS (Including	ng Author, Title, Date, Pertinent Pa	ges, Etc.)	***		
INITIAL	C61	Yanagihara, K. et al., "Transforming Growth Factor-Beta 1 Induces Apoptotic Cell Death in Cultured Human Gastric Carcinoma Cells," Cancer Res., 52:4042-4045 (1992).					
	C62	PCT International Search Report; PC	T/US97/16601		11-1		
	C63	Dolivet et al., "Current Knowledge On Laryngol. Otol. Rhinol. (Bord) 117(1):1	The Action Of Retinoids In Ca 9-26 (1996) (English abstract).	arcinoma Of The Hea	id And Neck," [Review], Rev.		
	C64	Etches et al., "Reptilian And Avian Fo Suppl. 4:112-122 (1990).	llicular Hierarchies: Models Fo	or The Study Of Ova	rian Development," J. Exp. Zoo.,		
	C65	Fukuda et al., "Induction Of Apoptosi Possible Associate With Tissue Transg	t al., "Induction Of Apoptosis By Transforming Growth Factor-1 In The Rat Hepatoma Cell Fine McA-RH77 Associate With Tissue Transglutaminase Expression," <i>Hepatology, 18:</i> 945-953 (1993).				
	C66	Gould, "Cancer Chemoprevention An	d Therapy By Monoterpenes,"	Environ. Health Pers	pect., 105 (Suppl 4):977-9 (1997).		
	C67	Kuo, "Antiproliferative Potency Of St 110(1-2):41-8 (1996).	urcturally Distinct Dietary Flav	vonoids On Human C	Colon Cancer Cells," Cancer Lett.,		
	C68	Mayr et al., "Sequence Of An Exon Of Tumour Suppressor p53 GeneA Comparative Study In Domestic Animals: Mutat In A Feline Comparative Study In Domestic Animals; Mutation In A Feline Solid Mammary Carcinoma," Br. Vet. J., 151(3):325-9 (1995).					
	C69	Wilson "Adeno-Carcinomata In Hens	Kept In A Constant Environm	ent," <i>Poult. Sci.</i> , 37:1	253 (1958).		
	C70	Milligan et al., "Programmed Cell Dea Holbrook, et al., (Eds), pp. 181-208 (19	oth During Development Of An 1996)	imals," <i>Cellular Agin</i>	ig and Cell Death: Wiley-Liss Inc.,		
	C71	Canman et al., "DNA Damage Responses: P-53 Induction, Cell Cycle Pertubations, And Apoptosis," Cold Spring Harbor Symp. Quant. Biol., 59:277-286 (1994)			poptosis," Cold Spring Harbor		
a	C72	Baker et al., "Etiology, Biology, And I	Epidemiology Of Ovarian Canc	er," Seminars in Sur	gical Oncology 10:242-248 (1994)		
EXAMINER	\frac{1}{2}		DATE CONSIDER	19/03			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		o E 💪	31140B	10/051662		
INF	FORMATION DESCLOSURE CITATION		Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker			
		(Use several shears if necessary)	Filing Date	Group Art Unit		
	H	EB 1 5 2002.	01/18/02	1614		
AMINER	V	THE THE DOCUMENTS (Including Author	r, Title, Date, Pertinent Pages, Etc.)			
NITIAL		Amos et al., "Genetic Epidemiology Of Epithel	lial Ovarian Cancer," Cancer 71:566-	72 (1993)		
∞	C73					
///						
7	C74	Wittemore, "Characteristics Relating To Ovar Oncology 55: S15-S19, 1994	ian Cancer Risk: Implications For Pi	reventing And Detection, Gynecologic		
		Greene et al., "The Epidemiology Of Ovarian	Cancer," Seminars in Oncology, 11:20	09-225 (1984)		
	C75					
_		Wittemore et al., "Characteristics Relating To	Ovarian Cancer Risk: Collaborative	Analysis Of 12 US Case-Control		
	C76	Studies," Am. J. Epidem. 136:1212-1220 (1992)				
	C76					
1		Wu et al., "Personal And Environmental Char	racteristics Related To Epithelial Ova	rian Cancer," Am. J. Epidem., 108(6):		
1	1216-1227 (1988)					
		Rossing et al., "Ovarian Tumors In A Cohort	Of Infertile Women," New Engl. J. M	led., 331:771-776 (1994)		
	C78					
			150	152 (1.1. 29 1070)		
		Casagrande et al., "Incessant Ovulation" and	"Ovarian Cancer," Lancet at pp. 170	-1/2 (July 28, 19/9)		
	C79					
		Rosenberg et al., (The WHO Collaborative Stud	L. Of Nearlagia And Stanoil Contraca	ntings)"A Case Control Study Of Oral		
		Contraceptive Use and Invasive Epithelial Ova	arian Cancer," Am. J. Epidem., 139:6	54-661 (1994)		
	C80					
		Stanford et al., "Epithelial Ovarian Cancer A	nd Combined Oral Contracentives."	Int'l J. Epidem., 18:538-545 (1989)		
		Stanioru et al., Epithenai Ovarian Cancer Al	nu Comomou Oran Common provide,			
	C81					
	-	Lee et al., "The Reduction In Risk Of Ovarian	Cancer Associated With Oral Contr	aceptive Use," New Engl. J. Med.,		
		316:650-655 (1987)				
	C82					
	11775	Gross et al., "The Estimated Effect Of Oral Co	ontraceptive Use On The Cumulative	Risk Of Epithelial Ovarian Cancer,"		
		Obstetrics Gynecology, 83:419-24 (1994)				
	C83					
7	-	Franseschi et al., "Pooled Analysis Of 3 Europ	pean Case-Control Studies Of Epithel	ial Ovarian Cancer: III. Oral		
1	C84	Contraceptive Use, " Int'l J. Cancer, 49:61-65	(1771)			
9	C84					
NER	5		DATE CONSIDERED			
	_//			~ ~		
///	///		1 11/9/6	<i>)</i> }		

			Docket Number (Optional)	Application Number		
	18	E JOHN THE CHANGE	Applicant(s)	10/051662		
INI	0	ATION ESCLOSURE CITATION (Use several	Gustavo C. Rodriguez and Regi	na Salas Whitaker Group Art Unit		
	\	3 1 5 2002	Filing Date 01/18/02	Group Art Unit		
*EXAMINER	An	TATE THER DOCUMENTS (Including Author, Title	le, Date, Pertinent Pages, Etc.)			
INITIAL	Rosenblatt et al., "High-Dose And Low-Dose Combined Oral Contraceptives: Protection Against Epithelial Ovar and The Length Of The Protective Effect," Eur. J. Cancer, 28A:1872-76, 1992 C85					
	C86	Stanford et al., (The WHO Collaborative Study Of N And Risk Of Epithelial Ovarian Cancer," Int'l J. C				
	C87	Liang et al., "Risk Of Breast, Uterine Corpus, And JAMA, 249:2909-2912 (1983)				
	C88	Wiley-Liss Inc., Holbrook et al., (Eds.), pp. 209-236	ident Apoptosis in Tumor Progression And In Cancer Therapy," Cellular Aging And Cell Death: ok et al., (Eds.), pp. 209-234 (1996).			
	C89		Death and Its Relationship to Aging,," Cellular Aging and Cell Death, Wiley-Liss Inc., 196).			
	C90	Bast et al., "Ovarian Cancer," Harrison's Principl McGraw-Hill, New York, Chapter 321, pp. 1853-1	es Of Internal Medicine, Thirteenth 858 (1994).	Edition, Isselbacher et al., (Eds.),		
	C91	Rodriguez et al., "Estrogen Replacmenet Therapy	And Fatal Ovarian Cancer," Am. J.	Epidem., 141:828-835 (1995).		
	C92	Dunn, I.C., et al., "The Effect of Photoperiodic His Reproduction on: <i>Poultry Science, Volume 71</i> , pp.	story On Egg Laying In Dwarf Broild 2090-2098 (1992).	r Hens," In: Physiology And		
	C93	Christopherson, W.A. et al., "Responsiveness Of H 1,25-Dihydroxycholecalciferol," Am. J. Obstet. Gyn	duman Carcinoma Cells Of Gynecolo necol., 155(6):1293-1296 (1986).	gic Origin To		
	C94	Moore, T.B., et al., "Differentiating Effects of 1,25 And Its Synergy With Retinoic Acid," <i>Journal Of Synergy With Retinoic Acid</i> ,"	-Dihydroxycholecalciferol (D3) on L Petriatric Hematology/Oncology, 17(4	a-N-5 Human Neuroblastoma Cells):311-317 (November, 1995).		
	C95	Rustin, G.J.S. et al., "Trial Of Isotretinoin And Ca Journal Of Cancer, 74(9):1479-1481 (1996).	alcitriol Monitored By CA 125 In Pat	ients With Ovarian Cancer," British		
Qn	C96	Saunders, D.E., et al., Repression Of c-myc Expres Twenty-Third Annual Meeting Of The Society Of G (1992) (ABSTRACT)	ssion In Ovarian Carcinoma Cells by Synecologic Oncologiest, March 15-18,	1,25-Dihydroxyvitamin D3," 1992. Gynecol. Oncol., 45(1):83-84		
EXAMINER	3		DATE CONSIDERED 3/19/03			
*EXAMINER:	Initial i	f citation considered, whether or not citation is in conformate copy of this form with next communication to applicant.	ance with MPEP Section 609; Draw line t	hrough citation if not in conformance and		

P09B/REV04

			Docket Number (Optional)	Application Number		
•		O.E.	31140B	10/051662		
INFORMATION DISCLOSURE CITATION O(Use several sheets if necessary)			Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker			
		FEB 1 5 2002	Filing Date 01/18/02	Group Art Unit 1614		
*EXAMINER	7	OTHER DOCUMENTS (Including Author, T.				
INITIAL		Saunders, D.E. et al., "Receptors for 1,25-Dihydr	oxyvitamin D3 in Gynecologic Neopl	asms," Gynecologic Oncology,		
(2)	C97	44(2):131-136 (1992).				
	C98	Saunders, D.E. et al., "Nonreproductive Hormon Meeting Of The Society Of Gynecologic Oncologies	st, rebruary 7-10, 1993. Gynecoi. Onc	01, 49(1).110 (1993) (ABSTRACT)		
	Saunders, D.E. et al., "Inhibition Of c-myc In Breast And Ovarian Carcinoma Cells By 1,25-Dihydroxyvitamin D3, Acid And Dexamethasone," <i>Anti-Cancer Drugs</i> , 4(2):201-208 (1993).					
	Saunders, D.E. et al., "Inhibition Of Breast And Ovarian Carcinoma Cell Growth By 1,25-Dihydroxyvitamin D3, Combi With Retonic Acid Or Dexamethasone," <i>Anti-Cancer Drugs</i> , 6(4):562-569 (1995).					
	C101	Biomarkers & Prevention, 2:467-472 (1993).	nd Protstate Cancer: A Prediagnostic Study With Stored Sera," Cancer Epidemiology, 12 (1993).			
Santiso-Mere et al., "Positive Regulation Of The Vitamin D Receptor By Its Cognate Ligand In Hete Systems," Molecular Endocrinology, 7(7):833-839 (1993).						
	C103	Davoodi et al., "Modulation Of Vitamin D Recep Breast Cancer Cells," J. Steroid Biochem. Molec.	tor And Estrogen Receptor By 1,25 (Biol., 54(3/4):147-153 (1995).	OH)2-Vitamin D3 In T-47D Human		
	C104	Colston et al., "1-25-Dihydroxyvitamin D3 And M Growth In Culture," <i>Endocrinology</i> , 108:1083-10	Malignant Melanoma: The Presence 186 (1981).	Of Receptors And Inhibition Of Cell		
Sato et al., "Antitumor Effect of 1a-Hydroxyvitamin D3," Tohoku J. Exp. Med., 136						
	C106	Eisman et al., "Suppression Of In Vivo Growth Of Human Cancer Solid Tumor Xenografts By 1,25-Dihydroxyvitamin D3," Cancer Research, 47:21-25 (1987).				
	C107	1,25-Dihydroxyvitamin D3 Receptor," Cancer Re	n et al., "Influence of 1,25-Dihydroxyvitamin D3 on Cultured Osteogenic Sarcoma Cells: Correlation With The Dihydroxyvitamin D3 Receptor," <i>Cancer Research</i> , 44:2103-2109 (1984).			
an	C108	Mangelsdorf et al., "1,25-Dihydroxyvitamin D3-induced Defferentiation In A Human Promyelocytic Leukemia Cell Line (HL-60): Receptor Mediated Maturation To Macrophage-Like Cells," <i>J. Cell. Biol.</i> , 98:391-398 (1984).				
EXAMINER		m	DATE CONSIDERED S 19/03	,		
*EXAMINER:	Initial if	citation considered, whether or not citation is in conform ecopy of this form with next communication to applicant	mance with MPEP Section 609; Draw line	through citation if not in conformance and		

			Docket Number (Optional)	Application Number			
,	/	E	31140B	10/051662			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker				
	(FEI	B 1 5 2002	Filing Date 01/18/02	Group Art Unit			
*EXAMINER	CAP.	HT& TRACTION HER DOCUMENTS (Including Author, Tu	(le, Date, Pertinent Pages, Etc.)				
INITIAL	Chida et al., "Inhibition Of Tumor In Mouse Skin By 1a, 25-Dihydroxyvitamin D31," Cancer Research, 45:5426-5430 (1985)						
M	C109						
	C110	Oikawa et al., Antitumor Effect Of 22-oxa-1a-Dihydroxyvitamin D3, A Potent Angiogenesis Inhibitor, On Rat Mammary Tumors Induced By 7,12-Dimethylbenz[a]anthracene," Anti-Cancer Drugs, 2:475-480 (1991).					
	Cili	Frampton et al., "Inhibition Of Human Cancer Cell Growth By 1,25-Dihydroxyvitamin D3 Metabolites1," Cancer Research, 43:4443-4447 (1983).					
	C112	Sporn, M.B. et al., "Prevention Of Carciogenesis Research, No. 34, Abstracts 622 (March, 1993).	esis With Vitamin D Analogs," Proceedings American Association For Cancer				
	C113	1,25-Dihydroxyvitamin D3," Gynecologic Oncolog	5-2 Endometrial Carcinoma Cell Growth By Carboplatin and acology, 51:155-159 (1993).				
	C114	Welsh, J., "Induction Of Apoptosis In Breast Cancer Cells In Response To Vitamin D And Antiestrogens," Biochem. Cell. Biol., 72:537-545 (1994).					
	C115	Narvaez et al., "Characterization Of A Vitamin D3-Resistant MCF-7 Cell Line," Endocrinology, 137(2):400-409 (1996).					
	C116	Lefkowitz et al., "Sunlight, Vitamin D, And Ovari Epidemiology, 23(6):1133-1136 (1994).	ian Cancer Mortality Rates In U.S. W	omen," International Journal Of			
73	C117	Studzinski et al., "Sunlight-Can It Prevent As Well As Cause Cancer?" Cancer Research, 55:4014-4022 (1995).					
	C118	Speroff et al., "Steroid Contraception," Clinical Gynecologic Endocrinology And Infirtility, Chapter 15, Fourth Edition, pp. 461-498 (1989).					
	Hammond, "Climateric," Danforth's Obstetrics And Gynecology, Chapter 42, Seventh Edition, pp. 771-790						
	C119						
B	C120	Young, "Gynecologic Malignancies, Ovarian Can 1605-608 (1994).	g, "Gynecologic Malignancies, Ovarian Cancer," <i>Harrison's Principles Of Internal Medicine</i> , Thirteenth Edition, pp. 608 (1994).				
EXAMINER			DATE CONSIDERED	3			
*EXAMINER	: Initial i	f citation considered, whether or not citation is in conform e copy of this form with next communication to applicant.	nance with MPEP Section 609; Draw line	through citation if not in conformance and			

•			Docket Number (Optional)	Application Number
	18	EVO	31140B	10/051662
INI		ATION SISCLOSURE CITATION (Use several species if necessary)	Applicant(s) Gustavo C. Rodriguez and Regina Salas Whitaker	
	FEB	1 5 2002	Filing Date 01/18/02	Group Art Unit 1614
*EXAMINER	CATE	AT A TRES	or, Title, Date, Pertinent Pages, Etc.)	
INITIAL	-	Ravin, L.J. et al., Remington's Pharmaceutical	I Sciences, 18th Ed., Chpts., 75-92 (1'	990, Mack Publishing Co., Easton, PA
0	C121	18042)		
	C122	Wingo, P.A. et al., "Cancer Statistics, 1995," (45(1):30 (1995)		
	C123	Dodd, R.C. et al., "Vitamin D Metabolites Cha 80:7538-7541 (December, 1983).		
	C124	Gao, Y. et al., "The Effects Of Chemotherapy 40(6):737-742 (1993).		
an) C125	United States Patent Appliation Serial No. 09/mailed on 06/22/01; Issue Fee paid by attorney	/479,021 filed on 01/07/00 (Inventor: y for applicant on 06/25/01	Rodriguez et al.); Notice of Allowance
EXAMINER			DATE CONSIDERED	19203
*EXAMINER:	: Initial if d. Includ	if citation considered, whether or not citation is in con- le copy of this form with next communication to applic	formance with MPEP Section 609; Dravicant.	v line through citation if not in conformance and